GUIDELINES AND RECOMMENDATIONS

Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography

Thomas Mathew1,a, Lynne Williams2,b, Govardhan Navaratnam3,b, Bushra Rana4,c, Richard Wheeler5,d, Katherine Collins6, Allan Harkness7, Richard Jones6, Dan Knight8, Kevin O’Gallagher9, David Oxborough10, Liam Ring11, Julie Sandoval12, Martin Stout13, Vishal Sharma14 and Richard P Steeds15, on behalf of the British Society of Echocardiography Education Committee

1Cardiology, Nottingham University Hospital, Nottingham, UK
2Cardiology, Papworth Hospital, Cambridge, UK
3University Health Board, Cwm Taf Health Board, Abercynon, UK
4Cardiac Services Directorate, Papworth Hospital, Cambridge, UK
5Cardiothoracic, University Hospital of Wales, Cardiff, UK
6Cardiology, Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, UK
7Cardiology Department, Colchester Hospital NHS Trust, Colchester, UK
8Centre for Cardiovascular Imaging, University College London, London, UK
9Cardiology, Kings College Hospital NHS Foundation Trust, London, UK
10Research Institute for Sports and Exercise Physiology, Liverpool John Moores University, Liverpool, UK
11Cardiology Department, West Suffolk Hospital NHS Trust, Bury St Edmonds, UK
12Cardiac Ultrasound, Leeds Teaching Hospitals NHS Trust, Leeds, UK
13Cardiology Department, University Hospital South Manchester, Manchester, UK
14Cardiology, Royal Liverpool University Hospital, Liverpool, UK
15Cardiology, University Hospital Birmingham and University of Birmingham, Birmingham, UK
(T Mathew is the Lead Author)
(L Williams and G Navaratnam contributed equally)
(B Rana is the Education Committee Chair)
(R Wheeler is the Lead for Protocols)

Abstract

Heart failure (HF) is a debilitating and life-threatening condition, with 5-year survival rate lower than breast or prostate cancer. It is the leading cause of hospital admission in over 65s, and these admissions are projected to rise by more than 50% over the next 25 years. Transthoracic echocardiography (TTE) is the first-line step in diagnosis in acute and chronic HF and provides immediate information on chamber volumes, ventricular systolic and diastolic function, wall thickness, valve function and the presence of pericardial effusion, while contributing to information on aetiology. Dilated cardiomyopathy (DCM) is the third most common cause of HF and is the most common cardiomyopathy. It is defined by the presence of left ventricular dilatation and left ventricular systolic dysfunction in the absence of abnormal loading conditions (hypertension and valve disease) or coronary artery disease sufficient to cause global systolic impairment. This document provides a practical approach to diagnosis and assessment of dilated cardiomyopathy that is aimed at the practising sonographer.

Key Words
- dilated cardiomyopathy
- echocardiography
- left ventricular dysfunction

Correspondence should be addressed to V Sharma
Email vishalsharma76@gmail.com
1. Introduction

1.1. The BSE Education Committee has previously published a minimum dataset for a standard adult transthoracic echocardiogram (TTE). These are published online in *Echo Research and Practice* (1). This document specifically states that the minimum dataset is usually only sufficient when the echocardiographic study is entirely normal. The aim of the Education Committee is to publish a series of appendices to cover specific pathologies to support this minimum dataset. This final document completes the cardiomyopathy series (hypertrophic (2), restrictive (3), ARVC (4) and dilated cardiomyopathies).

1.2. The intended benefits of such supplementary recommendations are to:

- Support cardiologists and echocardiographers to develop local protocols and quality control programmes for adult transthoracic study.
- Promote quality by defining a set of descriptive terms and measurements, in conjunction with a systematic approach to perform and report a study in specific disease states.
- Facilitate the accurate comparison of serial echocardiograms performed in patients at the same or different sites.

1.3. The views and measurements are focussed upon dilated cardiomyopathy and are supplementary to those outlined in the TTE minimum dataset. This document gives recommendations for the image and analysis dataset required in patients either being assessed for or with a known diagnosis of dilated cardiomyopathy.

1.4. When the condition or acoustic windows of the patient prevent the acquisition of one or more components of the supplementary dataset or when measurements result in misleading information (e.g. off-axis measurements) this should be stated.

1.5. This document is a guideline for echocardiography in dilated cardiomyopathy and will be updated in accordance with changes directed by publications or changes in practice.

2. Dilated cardiomyopathy

2.1. Dilated cardiomyopathy (DCM) is a progressive disease of the heart muscle. It is characterised by chamber enlargement and contractile dysfunction of the left ventricle in the absence of chronic pressure and/or volume overload. Although not essential for diagnosis, the right ventricle may similarly be affected. Dilated cardiomyopathy is the third most common cause of heart failure and is the commonest type of cardiomyopathy (5). The phenotype of ventricular dilatation and abnormal contractile dysfunction can be the result of a range of pathological conditions such as infection, toxins or autoimmune disease. However, in 50% of cases, the aetiology remains unknown and is termed ‘idiopathic DCM’. It is recognised that between 20% and 35% of idiopathic cases may have a family history suggesting an inherited gene defect (6).

2.2. Echocardiography is the first-line imaging test in the assessment of patients with DCM. It provides pivotal information not only for diagnosis, risk stratification and guiding treatment, but also plays a key role in screening family members. This document provides recommendations for the acquisition of images and collection of a dataset to be analysed during echocardiography in the assessment of patients with suspected or known DCM.

2.3. In this document, the parameters used for diagnosis and risk stratification are set out systematically (Table 1). Appendix 1 provides additional information on some of these parameters, Appendix 2 describes the echocardiographic features that help to differentiate the commonly encountered conditions presenting as DCM and finally a list of useful references for further reading.

2.4. The diagnostic criteria for DCM require exclusion of chronic pressure overload (such as hypertension and left ventricular outflow obstruction), chronic volume overload states (intra-cardiac shunts and valvular regurgitation) and ischaemic heart disease.
Table 1  Parameters used for diagnosis and risk stratification.

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLAX 2D/M-mode</td>
<td>LVIdd/s, IVSd, LVPWd</td>
<td>LV cavity size, wall thickness and radial function. Measurements are taken just distal to the mitral valve tip. If images are off axis, use 2D. All measurements should be indexed to BSA (refer to chamber quantification guidelines for normal values) (7).</td>
</tr>
<tr>
<td>Fractional shortening (FS)</td>
<td>LVIdd &gt;112% (2 s.d.) corrected for age and BSA is a diagnostic criterion for idiopathic DCM (refer to Appendix 1a). Value above 117% (2 s.d. plus 5%) increases the specificity and may be useful as a screening tool. FS &lt;25% is a criterion for the diagnosis of idiopathic DCM in the presence of a dilated ventricle.</td>
<td></td>
</tr>
<tr>
<td>PLAX M-mode</td>
<td>MV E-Septal separation (EPSS)</td>
<td>EPSS is defined as the minimal distance between E point (most anterior motion of the AML during diastole) and a line tangential to the most posterior excursion of the IVS within the same cardiac cycle. Normal range 0–5.3 mm. Value above 7 mm is indicative of reduced systolic function but a normal value does not exclude LV dysfunction (8, 9).</td>
</tr>
<tr>
<td>PLAX CFM</td>
<td>Mitral regurgitation</td>
<td>Assess mechanism and severity of mitral regurgitation. See Appendix 1a and MR dataset (10).</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1  Continued.

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSAX base to apex 2D</td>
<td>Qualitative assessment of ventricular (LV and RV) structure and function with special reference to radial systolic function and to exclude regional wall motion abnormalities</td>
<td>Refer to Appendix 2</td>
<td></td>
</tr>
<tr>
<td>A4C 2D</td>
<td>Qualitative assessment of ventricular (LV and RV) structure and function with special reference to radial and longitudinal function and regional wall motion abnormalities</td>
<td>Refer to Appendix 2</td>
<td></td>
</tr>
<tr>
<td>LV volumes</td>
<td>Diastolic and systolic volumes indexed to BSA (see BSE chamber quantification guide (7)). 3DE is recommended as the optimal method if endocardial definition is adequate Consider use of echo contrast if poor endocardial definition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ejection fraction (EF)</td>
<td>Estimated using Bi-plane Simpsons. 3DE is the preferred modality for measurement of LVEF EF of less than 45% is a diagnostic criterion for idiopathic DCM in the presence of a dilated ventricle (see Appendix 1a)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table 1  Continued.

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4C CFM</td>
<td>Sphericity index</td>
<td>Ratio between the length (mitral annulus to apex in the apical view) and width (mid-cavity level in the A4C view)</td>
<td><img src="image" alt="Image of Sphericity Index" /> 1.8 (d1/d2) in a non dilated LV with normal EF</td>
</tr>
<tr>
<td></td>
<td>(SI)</td>
<td>With gradual dilatation, left ventricle becomes more spherical in DCM and the value approaches near 1 (normal &gt;1.5)</td>
<td>SI of 1.2 in a patient with DCM</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>SI is a predictor of functional (exercise) capacity in patients with LV dysfunction and is an adverse prognostic marker</em> (11)</td>
<td>(Continued)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A4C PW</td>
<td>Mitral regurgitation</td>
<td>Assess mechanism and severity of MR Refer to Appendix 1a and MR dataset (10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LV inflow Doppler</td>
<td>E and A fusion is common in patients with DCM and indicates AV dysynchrony in the absence of sinus tachycardia</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Diastolic dysfunction

In patients with EF less than 45%, diastolic dysfunction coexists. In this group, grading of diastolic dysfunction can be performed using mitral inflow pattern alone and provides additional prognostic information

See BSE diastolic function guidelines for further information (12)

**Table 1 Continued.**

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4C tdi</td>
<td>S and e'</td>
<td>Both are decreased in DCM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Refer to diastolic function guidelines for age adjusted values (9)</td>
</tr>
<tr>
<td></td>
<td>Calculate E/e' ratio</td>
<td>e': an average from 2 sites (septal and lateral) is used for calculation of this ratio</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Value above 13 suggests raised LA pressure (12)</td>
</tr>
</tbody>
</table>

Grade I

Grade II

Grade III

(Continued)
Table 1  Continued.

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>A5C PW</td>
<td>Velocity time integral of LV outflow tract</td>
<td>&lt;18 cm is an adverse prognostic marker (13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indicative of a low flow state</td>
<td></td>
</tr>
<tr>
<td>Focussed RV view 2D</td>
<td>Basal LV:RV ratio</td>
<td>Qualitative assessment of RV size</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A ratio of &gt;0.66 suggests RV dilatation</td>
<td></td>
</tr>
<tr>
<td>RVD1</td>
<td></td>
<td>RVD1 &gt;41 mm; RVD2 &gt;35 mm; RVD3 &gt;83 mm indicates RV dilatation</td>
<td></td>
</tr>
<tr>
<td>RVD2</td>
<td></td>
<td>Refer to BSE ARVC dataset for further information on RV measurements and assessment (4)</td>
<td></td>
</tr>
<tr>
<td>RVD3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fractional area change (FAC)</td>
<td></td>
<td>FAC of &lt;35% indicates RV dysfunction</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RV dysfunction is not essential for the diagnosis of DCM but when present is an adverse prognostic marker (14)</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focused RV view M-mode</td>
<td>TAPSE</td>
<td>TAPSE of &lt;17 mm indicates RV systolic dysfunction</td>
<td></td>
</tr>
<tr>
<td>Focused RV view tdi</td>
<td>Tricuspid annulus S velocity</td>
<td>S velocity &lt;9.5 cm/s indicates RV systolic dysfunction</td>
<td></td>
</tr>
</tbody>
</table>

**Useful additional measurements**

| TR CW/CFM                   | Severity of TR and TR Vmax should be assessed in all views | See Appendix 1b **Raised PA pressure is an adverse prognostic marker (15)** |       |
| LA 2D/M-mode                | LA dimension and volume | Measured at end systole and BSA indexed. **LA dilatation suggests increased pressure and is an adverse prognostic marker (16)** (please refer to BSE chamber quantification guidelines for reference values) (7) |       |

(Continued)
### Table 1  Continued.

<table>
<thead>
<tr>
<th>View</th>
<th>Measurements</th>
<th>Explanatory note</th>
</tr>
</thead>
<tbody>
<tr>
<td>dp/dt CW</td>
<td>Measured from MR jet indicates change in LV pressure over time during systole</td>
<td>Record MR spectral profile at a high sweep speed (typically 100 mm/s). The time interval between the points at which the velocity is 1 m/s and 3 m/s is measured. According to the Bernoulli equation, the pressure increase in the left ventricle between these points is 32 mmHg ( \Delta P = 4 \times V_2^2 - 4 \times V_1^2 = 4 \times 3^2 - 4 \times 1^2 ). Thus, ( dp/dt ) (in mmHg/s) is calculated from the following formula: ( LV \ dp/dt \ max = 32 \ mmHg/time \ (s) ) ( dp/dt ) is a measure of global LV contractility Normal value: 1000–1200 mmHg/s ( dp/dt &lt; 600 \ mmHg/s ) is an adverse prognostic marker ((17)) See Appendix 1d</td>
</tr>
<tr>
<td>Dysynchrony indices M-mode</td>
<td>Septal to posterior wall delay</td>
<td>Septal to posterior wall delay of more than 130 ms suggest intraventricular dysynchrony Value of more than 30 ms between right and left ventricular pre ejection time suggests inter ventricular dysynchrony</td>
</tr>
<tr>
<td>Dysynchrony indices PW</td>
<td>Difference between RV and LV ejection time</td>
<td>Average delay of more than 65 ms from onset of QRS to peak S wave from 4 basal segments suggests intra ventricular dysynchrony</td>
</tr>
<tr>
<td>Dysynchrony indices TDI</td>
<td>Time from QRS onset to peak S wave from basal segments</td>
<td>Reduced aortic valve opening may be indicative of reduced stroke volume. However, if calcified may be due to primary AoV disease</td>
</tr>
<tr>
<td>Aortic valve M-mode</td>
<td>Pattern of aortic valve opening</td>
<td>Spontaneous contrast is commonly seen in dilated, poorly functioning chambers and should prompt assessment for intra cardiac thrombus</td>
</tr>
<tr>
<td>Thrombus 2D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Trans-oesophageal echocardiography

T Mathew and others Echocardiography in dilated cardiomyopathy

www.echorespract.com

Abbreviations

Views
A2C Apical two chamber
A4C Apical four chamber
A5C Apical five chamber
A3C Apical long axis or apical three chamber
PLAX Parasternal long axis
PSAX Parasternal short axis SC subcostal
SSN Suprasternal

Modality
CFM Colour flow Doppler
CW Continuous wave Doppler PW Pulse wave Doppler
TDI Tissue Doppler imaging

Explanatory test
2D 2-Dimensional echocardiography
3DE 3-Dimensional echocardiography
AML Anterior mitral valve leaflet
ARVC Arrhythmogenic right ventricular cardiomyopathy
AoV Aortic valve
AV Atrio-ventricular
BSA Body surface area
BSE British Society of Echocardiography
CRT Cardiac resynchronisation therapy
DCM dilated cardiomyopathy
dp/dt LV pressure rise in systole divided by time (rate of pressure rise)
e’ Early myocardial diastolic velocity on tissue Doppler imaging
E/e’ Ratio of MV E Vmax/ tissue Doppler early myocardial relaxation velocity
EF Ejection fraction
EPSS E point septal separation
FAC Fractional area change
FS Fractional shortening
ICM Ischaemic cardiomyopathy
IVS Interventricular septum
IVsd Interventricular septal thickness diastole
LA Left atrium
LV Left ventricle
LVId Left ventricular internal dimension in diastole
LVIds Left ventricular internal dimension in systole
LVNC Left ventricular non-compaction
LVPWd Left ventricular posterior (inferolateral) wall thickness in diastole
MR Mitral regurgitation
RV Right ventricle
RVD1 Right ventricular internal dimension
SI Sphericity index
S’ Peak myocardial systolic velocity on tissue Doppler imaging
TAPSE Tricuspid annular plane systolic excursion
TR Tricuspid regurgitation
PA Pulmonary artery
RV Right ventricle
RVD Right ventricular dimension
RVSP Right ventricular systolic pressure
TOE Trans-oesophageal echocardiography

Appendix 1: Important additional considerations

a. Diagnostic criteria: Diagnostic criteria of LV dilatation (>112% corrected to BSA and age) with reduced function (FS <25% and/or LVEF <45%) applies to ‘idiopathic’ DCM once secondary causes (hypertension, coronary artery disease, excess alcohol consumption, tachycardia-induced cardiomyopathy, systemic or pericardial disease, cor pulmonale and congenital heart disease) have been excluded (18, 19, 20). The value of 117% is equivalent to 2 s.d. from the upper normal limit corrected to age and BSA plus 5%. For the purposes of this guideline, it is recommended that a value above 2 s.d.s for age, sex and BSA should be used in diagnosis, using linear and volumetric methods, whether 2D or 3D.

b. Mitral regurgitation: MR is common in patients with DCM and is due to disease of the ventricle rather than a primary lesion of the mitral valve leaflets. Functional MR results from tethering of the leaflets secondary to a change in LV geometry leading to a tenting pattern. Identification of the mechanism of MR is important because chronic MR due to primary mitral valve disease can also present with findings similar to DCM. Echocardiographic features that suggest functional MR include the following (in the absence of any obvious morphological abnormality of the leaflets):

1. symmetric tenting of leaflets (asymmetric is more commonly seen in ischaemic CMP)
2. reduced leaflet coaptation zone*
3. central jet of MR
4. increased coaptation depth*
5. increased tenting area*
6. dilated mitral valve annulus
   *see European Association of Cardiovascular Imaging Valve Regurgitation Guidelines (21).

Trans-thoracic echocardiography usually differentiates primary from functional MR, but in a small proportion of patients, trans-oesophageal echocardiography may be required for further clarification.

c. Tricuspid regurgitation (TR): Functional TR in DCM is a marker of RV dilatation, RV dysfunction or pulmonary hypertension. Pulmonary artery pressure measured from TR velocity provides additional prognostic information in patients with DCM and should be assessed in all cases. Peak TR velocity of more than 2.5 m/s is associated with increased mortality, increased hospitalisation and higher incidence of heart failure (15).

d. Role of dysynchrony indices: Mechanical dysynchrony is common in patients with DCM and detection of
dysynchrony is important to identify patients who may benefit from cardiac resynchronisation therapy (CRT). Several echocardiographic parameters have been used to assess mechanical dysynchrony in small subsets of patients; however, the wider role of echocardiography in selecting patients for CRT is still debated. Currently, the role of echo is limited to patients with borderline QRS duration (120–149 ms) in which the presence of inter or intraventricular dysynchrony may provide additional information (22). Assessment of dysynchrony is therefore not part of the routine dataset for patients with DCM and should be used as an option in selected cases only.

e. Stress echo and contractile reserve: Assessment of contractile reserve by low-dose dobutamine stress echocardiography may refine prognosis in patients with DCM and may be used when cardiopulmonary exercise stress testing is not available or in patients who are unable to exercise. An increase in LV EF from rest to peak stress by $\geq$5% or a percentage change from baseline of $\geq$20% indicates the presence of contractile reserve. Its absence is an adverse prognostic marker (23).

f. Role of echo in family screening: Asymptomatic first-degree relatives of patients with idiopathic DCM should have an echocardiogram every 3–5 years or anytime signs or symptoms occur (24).

Appendix 2: Other related cardiomyopathic conditions

a. Ischaemic cardiomyopathy (ICM): Ischaemic cardiomyopathy can be differentiated from dilated cardiomyopathy by echocardiography in the vast majority of cases. LV dilatation in ICM usually occurs due to adverse remodelling after transmural myocardial infarction. During echocardiography, this is manifested by thinned, akinetic myocardial segments in the infarcted territory with cavity dilatation and mild compensatory hypertrophy of the non-infarcted segments. Infrequently, ICM can present as global hypokinesis mimicking DCM. When this occurs, it is usually in the presence of severe three-vessel coronary artery disease. In these situations, further assessment with stress echocardiography, stress cardiac MRI, coronary angiography or CT coronary angiography can be considered to exclude an ischaemic cause.

b. Left ventricular non-compaction cardiomyopathy (LVNC): LVNC is an unclassified cardiomyopathy and advanced cases can present with findings similar to DCM (i.e., a dilated and impaired left ventricle). Similarly, patients with DCM may have some echocardiographic features of LVNC which, if not recognised, can lead to over diagnosis. Echocardiographic criteria for the diagnosis of non-compaction include (25):

1. A two-layer structure with a compacted epicardial and non-compacted endocardial layer with maximal end systolic ratio of non-compacted to compacted layers of >2.

2. Predominant localisation of pathology to the apex, mid-lateral and mid-inferior segments.

3. Colour Doppler evidence of blood flow amid the myocardial wall deep recesses and LV cavity.

4. Absence of any other coexisting cardiac abnormalities (e.g. primary valve disease).

c. Peri-partum cardiomyopathy (PPCM): PPCM is an idiopathic cardiomyopathy that presents with heart failure secondary to left ventricular systolic dysfunction; usually seen towards the end of pregnancy or in the first 5 months after delivery; in the absence of any other cause of heart failure. A reduction in LV EF (usually <45%) is required to establish the diagnosis but the left ventricle may or may not be dilated. Other features are similar to DCM.

d. Toxic causes: A number of substances can be directly toxic to cardiac myocytes and result in depressed cardiac function and a phenotype of DCM. Most common agents include alcohol and chemotherapeutic drugs used for the treatment of cancers. Alcoholic cardiomyopathy most typically affects men between the ages of 35 and 50 years although women can also be affected. There is usually a long and significant history of heavy alcohol use. In addition to standard heart failure treatment, it is essential that affected patients abstain completely from alcohol. If identified at an early stage, cardiac function can improve with abstinence from alcohol but if severe LV dysfunction has developed, the damage may be irreversible. Chemotherapeutic drugs such as trastuzumab (Herceptin), anthracyclines and cyclophosphamide are most commonly implicated in causing impaired LV function. Regular monitoring for cardiotoxicity with serial echocardiography is usually recommended, and the chemotherapeutic agent may need to be stopped or changed if signs of cardiotoxicity develop. In addition conditions that result in excess iron deposition within the heart can lead to a phenotype of DCM. These include conditions such as hemochromatosis (genetic condition that results in excessive iron absorption) or conditions in which repeated blood transfusions
are required (secondary iron overload). Treatment of this includes iron chelation agents, and in some cases, repeated venesection. Recreational drug use, particularly with cocaine can also result in DCM.

e. Viral/infective causes: Viral infection can result in acute and chronic myocarditis with myocyte death. In the acute phase, this can be occasionally very severe with the development of severe LV dysfunction, occasionally necessitating mechanical circulatory support or cardiac transplantation. It has also been suggested that viral persistence is implicated in the development of idiopathic DCM (26). Infection with human immunodeficiency virus (HIV) can result in a number of cardiac manifestations including the development of DCM. If DCM develops in the context of HIV, it carries a particularly unfavourable prognosis.

f. Systemic disease: A number of other systemic diseases can be associated with DCM. These include generalised muscles disease such as muscular dystrophy, connective tissue diseases and vasculitis. Again, the presence of cardiac involvement in these conditions is an adverse prognostic marker.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this guideline.

Funding
This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

References

Received in final form 10 January 2017
Accepted 23 March 2017